DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Household
Updated 1y ago
B2A logo

Bioera S.p.A.DB:B2A Stock Report

Market Cap €810.5k
Updated 1y ago
Share Price
n/a
1Y-6.2%
7D0%
1D0%
Portfolio Value
​
View

Bioera S.p.A.

DB:B2A Stock Report

Market Cap: €810.5k

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bioera (B2A) Stock Overview

Engages in the production and sale of organic and herbal products, natural cosmetics, and traditional food products in Italy. More details

B2A fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (€810K)

Has not reported any financial data

Shares are highly illiquid


B2A Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW441,864 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
441,864 investors already sharing narratives
€
Current Price
€0.02461.3% undervalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-18m57m2016201920222025202620282031Revenue €1.2mEarnings €116.1k
Advanced
View all narratives

Bioera S.p.A. Competitors

LN Future Invest

Symbol: OM:LNFI
Market cap: SEK 10.2m

LifeQuest World

Symbol: OTCPK:LQWC
Market cap: US$2.0m

Rapid Nutrition

Symbol: ENXTPA:ALRPD
Market cap: €1.3m

Medicortex International

Symbol: NGM:MEDFIN
Market cap: SEK 3.8m

Price History & Performance

Summary of share price highs, lows and changes for Bioera
Historical stock prices
Current Share Price€0.024
52 Week High€0.11
52 Week Low€0.018
Beta0
1 Month Change0%
3 Month Change0%
1 Year Change-6.15%
3 Year Change-96.20%
5 Year Change-99.56%
Change since IPO-99.86%

Recent News & Updates

Recent updates

Shareholder Returns

B2ADE Personal ProductsDE Market
7D0%-2.5%-1.8%
1Y-6.2%-5.3%4.2%

Return vs Industry: B2A exceeded the German Personal Products industry which returned -7.3% over the past year.

Return vs Market: B2A underperformed the German Market which returned 14.7% over the past year.

Price Volatility

Is B2A's price volatile compared to industry and market?
B2A volatility
B2A Average Weekly Movementn/a
Personal Products Industry Average Movement4.2%
Market Average Movement5.0%
10% most volatile stocks in DE Market12.2%
10% least volatile stocks in DE Market2.5%

Stable Share Price: B2A's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine B2A's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20044Giorgio Campeggiowww.bioera.it

Bioera S.p.A. engages in the production and sale of organic and herbal products, natural cosmetics, and traditional food products in Italy. The company markets its products under the KI, Crudigno, and Fonte della Vita brand names; and distributes its products through outsourcers. The company was founded in 2004 and is headquartered in Milan, Italy.

Bioera S.p.A. Fundamentals Summary

How do Bioera's earnings and revenue compare to its market cap?
B2A fundamental statistics
Market cap€810.50k
Earnings (TTM)-€6.20m
Revenue (TTM)€1.15m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is B2A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B2A income statement (TTM)
Revenue€1.15m
Cost of Revenue€1.17m
Gross Profit-€21.00k
Other Expenses€6.18m
Earnings-€6.20m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did B2A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/03 19:55
End of Day Share Price 2024/12/04 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bioera S.p.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide